Population pharmacokinetics of tigecycline in critically ill patients with severe infections

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 8, 2017, Pages

  Xie, Jiao ^a,b   Roberts, Jason A ^b   Alobaid, Abdulaziz S ^b,c   Roger, Claire ^b   Wang, Yan ^a   Yang, Qianting ^a   Sun, Jinyao ^a   Dong, Haiyan ^a   Wang, Xue ^a   Xing, Jianfeng ^a   Lipman, Jeffrey ^b   Dong, Yalin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Riyadh Regional Laboratory   (Saudi Arabia)

Author keywords

Critically ill patients; Population pharmacokinetics; Severe infections; Tigecycline

Indexed keywords

TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ADULT; AGE; AGED; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DRUG DISTRIBUTION; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; KLEBSIELLA PNEUMONIAE; LOADING DRUG DOSE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATE CONSTANT; SKIN INFECTION; ANALOGS AND DERIVATIVES; BLOOD; CRITICAL ILLNESS; CROSS INFECTION; DRUG EFFECTS; GRAM NEGATIVE INFECTION; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MONTE CARLO METHOD; PHYSIOLOGY;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BODY MASS INDEX; CRITICAL ILLNESS; CROSS INFECTION; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; KLEBSIELLA PNEUMONIAE; MALE; METABOLIC CLEARANCE RATE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; MONTE CARLO METHOD; PROSPECTIVE STUDIES;

EID: 85026357323     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00345-17     Document Type: Article

References (17)

1. Pankey GA. 2005. Tigecycline. J Antimicrob Chemother 56:470–480. https://doi.org/10.1093/jac/dki248.
2. Dixit D, Madduri RP, Sharma R. 2014. The role of tigecycline in the treatment of infections in light of the new black box warning. Expert Rev Anti Infect Ther 12:397–400. https://doi.org/10.1586/14787210.2014.894882.
3. Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, Chuang Y-C, Maroko RT, Dukart G, Cooper CA. 2010. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 68:140–151. https://doi.org/10.1016/j.diagmicrobio.2010.05.012.
4. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. 2013. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 57:1756–1762. https://doi.org/10.1128/AAC.01232-12.
5. De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G, Spanu T, Tumbarello M, Antonelli M. 2014. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care 18:R90. https://doi.org/10.1186/cc13858.
6. Koomanachai P, Kim A, Nicolau DP. 2009. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. J Antimicrob Chemother 63:982–987. https://doi.org/10.1093/jac/dkp056.
7. Passarell JA, Meagher AK, Liolios K, Cirincione BB, Van Wart SA, Babinchak T, Ellis-Grosse EJ, Ambrose PG. 2008. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 52:204–210. https://doi.org/10.1128/AAC.00813-07.
8. Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, Ellis-Grosse EJ, Ambrose PG. 2007. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 51:1939–1945. https://doi.org/10.1128/AAC.01084-06.
9. Bhavnani SM, Rubino CM, Hammel JP, Forrest A, Dartois N, Cooper CA, Korth-Bradley J, Ambrose PG. 2012. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother 56:1065–1072. https://doi.org/10.1128/AAC.01615-10.
10. Van Wart SA, Owen JS, Ludwig EA, Meagher AK, Korth-Bradley JM, Cirincione BB. 2006. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob Agents Chemother 50:3701–3707. https://doi.org/10.1128/AAC.01636-05.
11. Rubino CM, Forrest A, Bhavnani SM, Dukart G, Cooper A, Korth-Bradley J, Ambrose PG. 2010. Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia. Antimicrob Agents Chemother 54:5180–5186. https://doi.org/10.1128/AAC.01414-09.
12. Pai MP. 2014. Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. J Antimicrob Chemother 69:190–199. https://doi.org/10.1093/jac/dkt299.
13. Barbour A, Schmidt S, Ma B, Schiefelbein L, Rand KH, Burkhardt O, Derendorf H. 2009. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet 48:575–584. https://doi.org/10.2165/11317100-000000000-00000.
14. Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein JT, Welte T. 2009. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents 34:101–102. https://doi.org/10.1016/j.ijantimicag.2009.01.015.
15. Xie J, Wang T, Wang X, Cheng X, Dong H, Wang Y, Zheng X, Zhou L, Xing J, Dong Y. 2014. Quantitative analysis and pharmacokinetics study of tigecycline in human serum using a validated sensitive liquid chromatography with tandem mass spectrometry method. J Sep Sci 37: 1396–1403. https://doi.org/10.1002/jssc.201400152.
16. Tatarinova T, Neely M, Bartroff J, van Guilder M, Yamada W, Bayard D, Jelliffe R, Leary R, Chubatiuk A, Schumitzky A. 2013. Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian. J Pharmacokinet Pharmacodyn 40: 189–199. https://doi.org/10.1007/s10928-013-9302-8.
17. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. 1981. APACHE—acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med 9:591–597. https://doi.org/10.1097/00003246-198108000-00008.